The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia

Annual Review of Pathology: Mechanisms of Disease

Volumn 9, Issue , 2014, Pages 239-271

  Bastian, Boris C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Classification; Genetics; Mutation; Nevi; Pathogenesis

Indexed keywords

ANIMAL; CLASSIFICATION; DISEASE COURSE; GENETICS; HUMAN; MELANOMA; MOLECULAR PATHOLOGY; MUTATION; PATHOLOGY; PIGMENTED NEVUS; PRECANCER; REVIEW; SKIN TUMOR;

ANIMALS; CLASSIFICATION; DISEASE PROGRESSION; HUMANS; MELANOMA; MUTATION; NEVUS, PIGMENTED; PATHOLOGY, MOLECULAR; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 84897018336     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012513-104658     Document Type: Article

References (148)

1. LeBoit PE, BurgG, Weedon D, Sarasin A, eds. 2006. World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours. Lyon, Fr.: IARC Press. http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb6/
2. Clark WH, Elder DE, Van Horn M. 1986. The biologic forms of malignant melanoma. Hum. Pathol. 17:443-50
3. Weyers W, Euler M, Diaz-Cascajo C, Schill WB, Bonczkowitz M. 1999. Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer 86:288-99
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-54
5. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, et al. 2003. Determinants of BRAF mutations in primary melanoma. J. Natl. Cancer Inst. 95:1878-90
6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, et al. 2005. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353:2135-47
7. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, et al. 2008. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 5:e120
8. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, et al. 2007. Distinct clinical and pathological features are associated with the BRAFT1799A(V600E) mutation in primary melanoma. J. Investig. Dermatol. 127:900-5
9. Purdue MP, From L, Armstrong BK, Kricker A, Gallagher RP, et al. 2005. Etiologic and other factors predicting nevus-Associated cutaneous malignant melanoma. Cancer Epidemiol. Biomark. Prev. 14:2015-22
10. Lachiewicz AM, Berwick M, Wiggins CL, ThomasNE. 2008. Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program. J. Investig. Dermatol. 128:243-45
11. Tsao H, Goel V, Wu H, Yang G, Haluska FG. 2004. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Investig. Dermatol. 122:337-41
12. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, et al. 2012. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44:1006-14
13. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. 2003. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J. Natl. Cancer Inst. 95:806-12
14. Pollock PM, HarperUL, Hansen KS, Yudt LM, Stark M, et al. 2003. High frequency of BRAF mutations in nevi. Nat. Genet. 33:19-20
15. Lin J, Takata M, Murata H, Goto Y, Kido K, et al. 2009. Polyclonality of BRAF mutations in acquired melanocytic nevi. J. Natl. Cancer Inst. 101:1423-27
16. YancovitzM, Litterman A, Yoon J, Ng E, Shapiro RL, et al. 2012. Intra- and inter-tumor heterogeneity of BRAFV600E mutations in primary and metastatic melanoma. PLoS ONE 7:e29336
17. Yeh I, von Deimling A, Bastian BC. 2013. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J. Natl. Cancer Inst. 105:917-19
18. Carr J, Mackie RM. 1994. Pointmutations in theN-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol. 131:72-77
19. Bastian BC, LeBoit PE, Pinkel D. 2000. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am. J. Pathol. 157:967-72
20. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, et al. 2009. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602
21. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, et al. 2010. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363:2191-99
22. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, et al. 2005. BRAFE600- associated senescence-like cell cycle arrest of human naevi. Nature 436:720-24
23. Tran SL, Haferkamp S, Scurr LL, Gowrishankar K, Becker TM, et al. 2012. Absence of distinguishing senescence traits in human melanocytic nevi. J. Investig. Dermatol. 132:2226-34
24. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. 2010. The essence of senescence. GenesDev. 24:2463-79
25. Kamijo T, Zindy F, RousselMF, Quelle DE, Downing JR, et al. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-59
26. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602
27. Kamb A. 1994. Role of a cell cycle regulator in hereditary and sporadic cancer. Cold Spring Harb. Symp. Quant. Biol. 59:39-47
28. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, et al. 1994. Germline p16 mutations in familial melanoma. Nat. Genet. 8:15-21
29. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, et al. 1996. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA 93:8541-45
30. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, et al. 2006. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uvealmelanoma acrossGenoMEL. Cancer Res. 66:9818-28
31. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, et al. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12:97-99
32. Randerson-Moor JA, HarlandM, Williams S, Cuthbert-Heavens D, Sheridan E, et al. 2001. A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10:55-62
33. Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, et al. 2004. Longitudinal assessment of the nevus phenotype in a melanoma kindred. J. Investig. Dermatol. 123:576-82
34. Bishop JAN, Wachsmuth RC, Harland M, Bataille V, Pinney E, et al. 2000. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J. Investig. Dermatol. 114:28-33
35. Gorgoulis VG, Vassiliou L-VF, Karakaidos P, Zacharatos P, Kotsinas A, et al. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-13
36. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. 2003. Classifying melanocytic tumors based on DNA copy number changes. Am. J. Pathol. 163:1765-70
37. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, et al. 2013. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 3:1252-65
38. Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, et al. 2008. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133:1019-31
39. Maldonado JL, Timmerman L, Fridlyand J, Bastian BC. 2004. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am. J. Pathol. 164:1783-87
40. Ramirez RD, DAtri S, Pagani E, FaraggianaT, Lacal PM, et al. 1999. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma. Neoplasia 1:42-49
41. Rudolph P, Schubert C, Tamm S, Heidorn K, Hauschild A, et al. 2000. Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am. J. Pathol. 156:1425-32
42. Bastian BC, Kashani-Sabet M, Hamm H, Godfrey T, Moore DH, et al. 2000. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60:1968-73
43. North JP, Kageshita T, Pinkel D, LeBoit PE, Bastian BC. 2008. Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J. Investig. Dermatol. 128:2024-30
44. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. 2013. TERT promoter mutations in familial and sporadic melanoma. Science 339:959-61
45. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. 2013. Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-59
46. Bastian BC. 2003. Hypothesis: a role for telomere crisis in spontaneous regression of melanoma. Arch. Dermatol. 139:667-68
47. Sekulic A, Colgan MB, Davis MDP, DiCaudo DJ, Pittelkow MR. 2010. Activating BRAF mutations in eruptive melanocytic naevi. Br. J. Dermatol. 163:1095-98
48. Kang T-W, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, et al. 2011. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479:547-51
49. Hodis E, Watson IR, Kryukov GV, Arold ST, ImielinskiM, et al. 2012. A landscape of driver mutations in melanoma. Cell 150:251-63
50. Ceol CJ, HouvrasY, Jane-Valbuena J, Bilodeau S, Orlando DA, et al. 2011. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 471:513-17
51. MacGregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, et al. 2011. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat. Genet. 43:1114-18
52. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. 2007. Expression of polycomb group protein EZH2 in nevi and melanoma. J. Cutan. Pathol. 34:597-600
53. Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, SeguraMF, et al. 2010. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468:1105-9
54. Hoon DSB, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. 2004. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014-22
55. Liu S, Ren S, Howell P, FodstadO, Riker AI. 2008. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 21:545-58
56. Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, et al. 2007. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 3:e181
57. Lian CG, Xu Y, Ceol C, Wu F, Larson A, et al. 2012. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:1135-46
58. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, et al. 2010. Impaired hydroxylation of 5- methylcytosine in myeloid cancers with mutant TET2. Nature 468:839-43
59. FigueroaME, Abdel-WahabO, LuC, Ward PS, Patel J, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-67
60. Harbour JW, Onken MD, Roberson EDO, Duan S, Cao L, et al. 2010. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410-13
61. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, et al. 2011. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43:1018-21
62. Wiesner T, Murali R, Fried I, Cerroni L, Busam K, et al. 2012. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am. J. Surg. Pathol. 36:818-30
63. Reimer RR, Clark WH, Greene MH, Ainsworth AM, Fraumeni JF. 1978. Precursor lesions in familial melanoma: a new genetic preneoplastic syndrome. JAMA 239:744-46
64. Piepkorn M, Meyer LJ, Goldgar D, Seuchter SA, Cannon-Albright LA, et al. 1989. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J. Am. Acad. Dermatol. 20:407-15
65. Ackerman AB. 1988. What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 13:241-56
66. Duncan LM, Berwick M, Bruijn JA, ByersHR, Mihm MC, Barnhill RL. 1993. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J. Investig. Dermatol. 100:S318-21
67. Ackerman AB, Milde P. 1992. Naming acquired melanocytic nevi. Common and dysplastic, normal and atypical, or Unna, Miescher, Spitz, and Clark? Am. J. Dermatopathol. 14:447-53
68. GoldgarDE, Cannon-Albright LA, Meyer LJ, PipekornMW, Zone JJ, Skolnick MH. 1991. Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. J. Natl. Cancer Inst. 83:1726-33
69. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, et al. 1997. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 277:1439-44
70. Hussein MRA-E, Wood GS. 2002. Molecular aspects of melanocytic dysplastic nevi. J. Mol. Diagn. 4:71-80
71. Whiteman DC, Pavan WJ, Bastian BC. 2011. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 24:879-97
72. BusamKJ, Murali R, PulitzerM, McCarthy SW, Thompson JF, et al. 2009. Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am. J. Surg. Pathol. 33:1386-95
73. Ludgate MW, Fullen DR, Lee J, Lowe L, Bradford C, et al. 2009. The atypical Spitz tumor of uncertain biologic potential. Cancer 115:631-41
74. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, et al. 2006. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355:1307-17
75. Lange JR, Palis BE, Chang DC, Soong S-J, Balch CM. 2007. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J. Clin. Oncol. 25:1363-68
76. Crombie IK. 1979. Variation of melanoma incidence with latitude in North America and Europe. Br. J. Cancer 40:774-81
77. Elwood JM, GallagherRP. 1998. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int. J. Cancer 78:276-80
78. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, et al. 2009. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191-96
79. Mocellin S, Verdi D, Nitti D. 2009. DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-Analysis. Carcinogenesis 30:1735-43
80. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, et al. 2012. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44:133-39
81. Besaratinia A, Pfeifer GP. 2008. Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum. Mutat. 29:983-91
82. Noonan FP, Zaidi MR, Wolnicka-Glubisz A, Anver MR, Bahn J, et al. 2012. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat. Commun. 3:884
83. Agrup G, Hansson C, Rorsman H, Rosengren E. 1982. The effect of cysteine on oxidation of tyrosine, dopa, and cysteinyldopas. Arch. Dermatol. Res. 272:103-15
84. Simon JD, Peles DN. 2010. The red and the black. Acc. Chem. Res. 43:1452-60
85. Song X, Mosby N, Yang J, Xu A, Abdel-Malek Z, Kadekaro AL. 2009. α-MSH activates immediate defense responses to UV-induced oxidative stress in human melanocytes. Pigment Cell Melanoma Res. 22:809-18
86. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. 1995. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat. Genet. 11:328-30
87. Brown KM, MacGregor S, Montgomery GW, Craig DW, Zhao ZZ, et al. 2008. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet. 40:838-40
88. Han J, Kraft P, Nan H, Guo Q, Chen C, et al. 2008. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet. 4:e1000074
89. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, et al. 2009. Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 41:920-25
90. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JAN, et al. 2009. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 41:915-19
91. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, Montgomery GW. 2010. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J. Investig. Dermatol. 130:520-28
92. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, et al. 2011. Genome-wide association study identifies three new melanoma susceptibility loci. Nat. Genet. 43:1108-13
93. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, et al. 2006. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313:521-22
94. Fargnoli MC, Pike K, Pfeiffer RM, Tsang S, Rozenblum E, et al. 2008. MC1R variants increase risk of melanomas harboring BRAF mutations. J. Investig. Dermatol. 128:2485-90
95. Thomas NE, Kanetsky PA, Edmiston SN, Alexander A, Begg CB, et al. 2010. Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study. J. Investig. Dermatol. 130:1463-65
96. Hacker E, HaywardNK, Dumenil T, James MR, Whiteman DC. 2010. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J. Investig. Dermatol. 130:241-48
97. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, et al. 2012. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18:3242-49
98. Hacker E, Nagore E, Cerroni L, Woods SL, Hayward NK, et al. 2013. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. J. Invest. Dermatol. 133:1027-33
99. Olah J, Toth-Molnar E, Kemeny L, Csoma Z. 2013. Long-term hazards of neonatal blue light phototherapy. Br. J. Dermatol. 169:243-49
100. Bauer J, Buttner P, Wiecker TS, Luther H, Garbe C. 2005. Effect of sunscreen and clothing on the number of melanocytic nevi in 1, 812 German children attending day care. Am. J. Epidemiol. 161:620-27
101. Green A, Autier P, Boniol M, Boyle P, Dore J-F, et al. (Int. Agency Res. Cancer Work. Group Artif. Ultrav. Light Skin Cancer). 2007. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int. J. Cancer 120:1116-22
102. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. 2003. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J. Natl. Cancer Inst. 95:806-12
103. Glatz-Krieger K, PacheM, Tapia C, Fuchs A, Savic S, et al. 2006. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uvealmelanomas detected by fluorescence in situ hybridization. Virchows Arch. 449:328-33
104. Curtin JA, Busam K, Pinkel D, Bastian BC. 2006. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24:4340-46
105. Davison JM, Rosenbaum E, Barrett TL, Goldenberg D, Hoque MO, et al. 2005. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 103:788-92
106. Saida T. 2000. Malignant melanoma on the sole: how to detect the early lesions efficiently. Pigment Cell Res. 13:135-39
107. Arrington JH3rd, Reed RJ, IchinoseH, Krementz ET. 1977. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am. J. Surg. Pathol. 1:131-43
108. Chang AE, Karnell LH, Menck HR. 1998. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84, 836 cases from the past decade. Cancer 83:1664-78
109. Kuchelmeister C, Schaumburg-Lever G, Garbe C. 2000. Acral cutaneous melanoma in Caucasians: clinical features, histopathology and prognosis in 112 patients. Br. J. Dermatol. 143:275-80
110. McLaughlin CC, WuXC, Jemal A, Martin HJ, Roche LM, Chen VW. 2005. Incidence of noncutaneous melanomas in the U.S. Cancer 103:1000-7
111. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, et al. 2008. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14:6821-28
112. Van Dijk M, Sprenger S, Rombout P, Marres H, Kaanders J, et al. 2003. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization. Genes Chromosomes Cancer 36:151-58
113. Park E, Yang S, Emley A, DeCarlo K, Richards J, Mahalingam M. 2012. Lack of correlation between immunohistochemical expression ofCKITand KIT mutations in atypical acral nevi. Am. J.Dermatopathol. 34:41-46
114. Alexeev V, Yoon K. 2006. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J. Investig. Dermatol. 126:1102-10
115. Monsel G, Ortonne N, Bagot M, Bensussan A, Dumaz N. 2009. c-Kitmutants require hypoxia-inducible factor 1αto transform melanocytes. Oncogene 29:227-36
116. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M. 1998. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 17:4358-69
117. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman R-A, et al. 2011. KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-34
118. Watt AJ, Kotsis SV, Chung KC. 2004. Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast. Reconstr. Surg. 113:1968-74
119. Mancianti ML, Clark WH, Hayes FA, Herlyn M. 1990. Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am. J. Pathol. 136:817-29
120. Bastian BC, Xiong J, Frieden IJ, Williams ML, Chou P, et al. 2002. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am. J. Pathol. 161:1163-69
121. Bauer J, Curtin JA, Pinkel D, Bastian BC. 2007. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J. Investig. Dermatol. 127:179-82
122. Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, et al. 2013. Multiple congenital melanocytic naevi and neurocutaneous melanosis are caused by post-zygotic mutations in codon 61 of NRAS. J. Investig. Dermatol. 133:2229-36
123. Slutsky JB, Barr JM, Femia AN, Marghoob AA. 2010. Large congenital melanocytic nevi: associated risks and management considerations. Semin. Cutan. Med. Surg. 29:79-84
124. Van RaamsdonkCD, FitchKR, FuchsH, deAngelisMH, Barsh GS. 2004. Effects ofG-protein mutations on skin color. Nat. Genet. 36:961-68
125. Dessars B, De Raeve LE, Housni HE, DebouckCJ, Sidon PJ, et al. 2007. Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi. J. Investig. Dermatol. 127:1468-70
126. Murali R, McCarthy SW, Scolyer RA. 2009. Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. Adv. Anat. Pathol. 16:365-82
127. Sherman L, Stocker KM, Morrison R, Ciment G. 1993. Basic fibroblast growth factor (bFGF) acts intracellularly to cause the transdifferentiation of avian neural crest-derived Schwann cell precursors into melanocytes. Development 118:1313-26
128. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, et al. 2000. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat. Genet. 26:89-92
129. Maize JC, McCalmont TH, Carlson JA, Busam KJ, Kutzner H, Bastian BC. 2005. Genomic analysis of blue nevi and related dermal melanocytic proliferations. Am. J. Surg. Pathol. 29:1214-20
130. Martin RCW, Murali R, Scolyer RA, Fitzgerald P, Colman MH, Thompson JF. 2009. So-called "malignant blue nevus." Cancer 115:2949-55
131. Murali R, Wiesner T, Rosenblum M, Bastian B. 2012. GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathol. 123:457-59
132. Brat DJ. 2010. Melanocytic neoplasms of the central nervous system. In Practical Surgical Neuropathology, ed. A Perry, DJ Brat, pp. 353-59. Philadelphia: Churchill Livingstone
133. Singh AD, Turell ME, Topham AK. 2011. Uvealmelanoma: trends in incidence, treatment, and survival. Ophthalmology 118:1881-85
134. Singh AD, Kalyani P, Topham A. 2005. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology 112:1784-89
135. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. 1996. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347:1222-25
136. Dey A, Seshasayee D, Noubade R, French DM, Liu J, et al. 2012. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337:1541-46
137. OnkenMD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. 2006. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 66:4602-9
138. Harbour JW, Roberson EDO, Anbunathan H, Onken MD, Worley LA, Bowcock AM. 2013. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45:133-35
139. An M, Henion PD. 2012. The zebrafish sf3b1b460 mutant reveals differential requirements for the sf3b1 pre-mRNA processing gene during neural crest development. Int. J. Dev. Biol. 56:223-37
140. Sommer L. 2011. Generation of melanocytes from neural crest cells. Pigment CellMelanoma Res. 24:411-21
141. Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, et al. 2002. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416:854-60
142. Granter SR, McKee PH, Calonje E, MihmMCJr, Busam K. 2001. Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus: a clinicopathologic study of 10 cases on the spectrum of so-called "malignant blue nevus." Am. J. Surg. Pathol. 25:316-23
143. Lens MB, Newton-Bishop JA, Boon AP. 2005. Desmoplastic malignant melanoma: a systematic review. Br. J. Dermatol. 152:673-78
144. Busam KJ. 2011. Desmoplastic melanoma. Clin. Lab. Med. 31:321-30
145. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, et al. 2002. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. J. Dermatol. 147:62-70
146. Bradford PT, Goldstein AM, McMaster ML, TuckerMA. 2009. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch. Dermatol. 145:427-34
147. Hu D-N, Yu G-P, McCormick SA, Schneider S, Finger PT. 2005. Population-based incidence of uveal melanoma in various races and ethnic groups. Am. J. Ophthalmol. 140:612e1-8
148. Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, et al. 2011. Outcomes in pediatric melanoma. Ann. Surg. 253:1211-15